-
2 months ago | 
radcliffecardiology.com | Pam R Taub |David Power
Time-restricted eating in comparison to standard of care for patients with metabolic syndrome caused a reduction in hemoglobin A1C, LDL cholesterol, and body fat. What do these benefits suggest for the future of metabolic syndrome management?
-
Nov 6, 2024 | 
healio.com | Emma Bascom |Pam R Taub |Carol L. DiBerardino
You've successfully added Diabetes in Primary Care to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Time-restricted eating can reduce type 2 diabetes risk and improve overall health in those with metabolic syndrome.
-
Oct 18, 2024 | 
healio.com | Scott Buzby |Erik Swain |Pam R Taub
Read more You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Cardiology health care professionals expressed hesitancy in prescribing FDA-approved obesity medications to reduce ASCVD risk.
-
Sep 30, 2024 | 
newswise.com | Pam R Taub
It is estimated that more than one-third of adults in the United States have metabolic syndrome, a grouping of medical conditions that can lead to heart disease, diabetes and stroke. Risk factors attributing to the syndrome include elevated blood sugar, high blood pressure and high cholesterol.
-
Jul 12, 2024 | 
radcliffecardiology.com | Vlado Perkovic |Kevin Cheng |Jonathan Hill |Pam R Taub
ADA 24 - In this succinct video, we are joined by Dr Vlado Perkovic (UNSW Sydney, Kensington, AU) to discuss a trial investigating the use of semaglutide in patients with type 2 diabetes and chronic kidney disease (NCT03819153). The FLOW trial enrolled 3533 participants with type 2 diabetes and chronic kidney disease, who were then randomized to recieve either semaglutide or placebo. The median follow-up period was 3.4 years, as the trial was stopped early at a prespecified interim analysis.
-
Jul 5, 2024 | 
radcliffecardiology.com | Pam R Taub |Nikolaus Marx |Michel Komajda |Sven Francque
RP-UN-CAR-GB-0166 / June 2024This programme features a compelling discussion between two distinguished experts, Prof Pam Taub (University of California, San Diego, US) and Prof Nikolaus Marx (University Hospital RWTH, Aachen, DE), chairperson responsible for the most recent ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes.
-
Feb 27, 2024 | 
medscape.com | Pam R Taub |Kamala Tamirisa |Jonathan P. Piccini
closePlease confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. The management of atrial fibrillation must take into account its progressive and chronic nature, and early diagnosis and treatment are key to achieving optimal patient outcomes. What are the main shifts in the treatment strategies and what questions still remain unanswered?
-
Jan 11, 2024 | 
hcplive.com | C. Michael Gibson |Payal Kohli |Manesh R. Patel |Pam R Taub
SummaryThe experts envision increased use of targeted therapies like siRNA that allow less frequent dosing for hypercholesterolemia and other conditions. Exciting data on “one-and-done” gene editing may enable permanent PCSK9 inhibition in familial hypercholesterolemia. Such innovations promise elegant, well-tolerated long-term solutions.
-
Jan 11, 2024 | 
hcplive.com | C. Michael Gibson |Payal Kohli |Manesh R. Patel |Pam R Taub
SummaryThe experts discuss considerations around selecting non-statin therapies for high cholesterol, either as add-on options to maximally tolerated statins or alternatives for statin-intolerant patients. The choice depends on the degree of additional LDL lowering required to reach one's personalized LDL "end zone" or target. If the LDL is not too far from goal, options like ezetimibe, which reduces LDL around 20%, may suffice.
-
Jan 11, 2024 | 
hcplive.com | C. Michael Gibson |Payal Kohli |Manesh R. Patel |Pam R Taub
January 11, 2024Expert cardiologists discuss the recent clinical trials results of the CLEAR-OUTCOMES trial and thee sub analysis on the inflammatory marker hcCRP. SummaryThe experts discuss the CLEAR Outcomes trial results for the newer cholesterol-lowering agent bempedoic acid in statin-intolerant patients. This 14,000-patient trial included a mix of primary and secondary prevention patients and demonstrated a significant reduction in 3-point major adverse cardiovascular events (MACE).
